330 filings
8-K
INMB
INmune Bio Inc
23 May 24
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
INMB
INmune Bio Inc
16 May 24
Departure of Directors or Certain Officers
4:00pm
8-K
INMB
INmune Bio Inc
10 May 24
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a
7:46pm
10-Q
2024 Q1
INMB
INmune Bio Inc
Quarterly report
9 May 24
4:05pm
S-3
INMB
INmune Bio Inc
Shelf registration
1 May 24
4:05pm
8-K
8bdk8 spvakyqap
30 Apr 24
Other Events
4:01pm
8-K
cg38xk75j zibje
26 Apr 24
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:28pm
424B5
c1fhdecvtol5iv
26 Apr 24
Prospectus supplement for primary offering
4:26pm
8-K
mxe50
25 Apr 24
Other Events
4:35pm
8-K
jjvupej22g
22 Apr 24
Entry into a Material Definitive Agreement
5:10pm
424B5
s8hbbe
22 Apr 24
Prospectus supplement for primary offering
5:09pm
8-K
bca9d u3je2k
9 Apr 24
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
4:58pm
8-K
i1gxn2sn7vqdq
29 Mar 24
INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
4:01pm
8-K
ff142s9
27 Mar 24
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
4:07pm
8-K
1k6fbxcdshp6tc4rar
30 Jan 24
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
8:02am
8-K
8b8d6m
2 Jan 24
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
4:00pm
8-K
fpjtej
18 Dec 23
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
4:15pm
8-A12B/A
60kyzxzwj4hhs2
18 Dec 23
Registration of securities on exchange (amended)
4:05pm